Roivant Sciences Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Year Ending	TTM	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	6,536	6,536	1,677	2,060	2,133	2,185
Cash & Cash Equivalents	6,536	6,536	1,677	2,060	2,133	2,185
Cash Growth	289.77%	289.77%	-18.62%	-3.39%	-2.41%	-
Other Current Assets	196.12	196.12	121.77	86.12	54.25	33.76
Total Current Assets	6,732	6,732	1,799	2,147	2,187	2,219
Property, Plant & Equipment	65.95	65.95	92.34	86.95	77.03	73.93
Long-Term Investments	247.75	247.75	304.32	325.83	298.47	177.22
Goodwill and Intangibles	137.84	137.84	144.88	0	0	0
Other Long-Term Assets	39.11	39.11	49.48	25.82	27.2	6.66
Total Long-Term Assets	490.65	490.65	591.02	438.61	402.7	257.81
Total Assets	7,222	7,222	2,390	2,585	2,590	2,477
Accounts Payable	53.23	53.23	37.83	34.58	20.55	10.31
Deferred Revenue	0	0	0	0	5.92	0
Current Debt	21.89	21.89	52.41	11.4	12.31	7.84
Other Current Liabilities	191.64	191.64	182.21	138.39	180.18	73.97
Total Current Liabilities	266.76	266.76	272.45	184.37	218.96	92.12
Long-Term Debt	477.86	477.86	428.99	272.49	232.66	173.04
Other Long-Term Liabilities	29.34	29.34	80.58	66.84	76.06	103.19
Total Long-Term Liabilities	507.2	507.2	509.57	339.33	308.73	276.24
Total Liabilities	773.95	773.95	782.02	523.7	527.69	368.36
Total Debt	499.75	499.75	481.4	283.89	244.98	180.88
Debt Growth	3.81%	3.81%	69.57%	15.88%	35.43%	-
Retained Earnings	576.17	576.17	-3,772.75	-2,763.72	-1,918.46	-1,109.23
Comprehensive Income	-4.08	-4.08	-2.62	-0.95	1.45	-2.35
Shareholders' Equity	5,969	5,969	1,158	1,657	1,798	2,032
Net Cash / Debt	6,036	6,036	1,195	1,777	1,888	2,005
Net Cash / Debt Growth	404.93%	404.93%	-32.71%	-5.89%	-5.83%	-
Net Cash Per Share	7.26	7.26	1.68	2.65	3.00	9.15
Working Capital	6,465	6,465	1,526	1,962	1,968	2,127
Book Value Per Share	7.62	7.62	1.62	2.47	2.85	9.28

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).